IP Verse

Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab - EP2676967

The patent EP2676967 was granted to Biogen Idec MA on Aug 14, 2019. The application was originally filed on Feb 28, 2007 under application number EP13175987A. The patent is currently recorded with a legal status of "Revoked".

EP2676967

BIOGEN IDEC MA
Application Number
EP13175987A
Filing Date
Feb 28, 2007
Status
Revoked
Feb 17, 2023
Publication Date
Aug 14, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

POLPHARMA BIOLOGICSMay 14, 2020WICHMANN -

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2002197233
DESCRIPTIONUS5840299
DESCRIPTIONUS6033665
DESCRIPTIONUS6551593
DESCRIPTIONUS6602503

Non-Patent Literature (NPL) Citations (128) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AGOSTINI ET AL., J. CLIN. MICROBIOL, (1996), vol. 34, pages 159 - 164
DESCRIPTION- AGOSTINI ET AL., J. CLIN. MICROBIOL., (1996), vol. 34, pages 159 - 164
DESCRIPTION- BARON ET AL., EXP. MED., (1993), vol. 177, pages 57 - 68
DESCRIPTION- BARON ET AL., J. EXP. MED., (1993), vol. 177, pages 57 - 68
DESCRIPTION- BERGER ET AL., ANN. NEUROL., (1998), vol. 44, pages 341 - 349
DESCRIPTION- BITSCH ET AL., BRAIN, (2000), vol. 123, pages 1174 - 1183
DESCRIPTION- BJARTMAR ET AL., J. NEUROCYTOL., (1999), vol. 28, pages 383 - 395
DESCRIPTION- BJARTMAR; TRAPP, CURR. OPIN. NEUROL., (2001), vol. 14, pages 271 - 278
DESCRIPTION- BROCKE ET AL., PROC. NATL. ACAD. SCI., (1999), vol. 96, pages 6896 - 6901
DESCRIPTION- BRUCK ET AL., ANN. NEUROL., (1997), vol. 42, pages 783 - 793
DESCRIPTION- CANNELLA; RAINE, ANN. NEUROL., (1995), vol. 37, pages 424 - 435
DESCRIPTION- CHABAS ET AL., SCIENCE, (2001), vol. 294, pages 1731 - 1735
DESCRIPTION- CHANG ET AL., J. NEUROVIROL., (2002), vol. 8, pages 447 - 451
DESCRIPTION- CHRISTENSEN ET AL., J. IMMUNOL., (1995), vol. 154, pages 5293 - 5301
DESCRIPTION- CLIFFORD ET AL., NEUROLOGY, (1999), vol. 52, pages 623 - 625
DESCRIPTION- COLLAZOS, CNS DRUGS, (2003), vol. 17, pages 869 - 887
DESCRIPTION- CROWDER ET AL., AM. J. TRANSPLANT, (2005), vol. 5, pages 1151 - 1158
DESCRIPTION- DEMETER ET AL., Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th edition, (1995), vol. 2, pages 1400 - 1406
DESCRIPTION- DORE-DUFFY ET AL., Frontiers in Cerebral Vascular Biology: Transport and Its Regulation, PLENUM, (1993), pages 243 - 248
DESCRIPTION- DORRIES ET AL., J. NEUROVIROL, (2003), vol. 9, no. 1, pages 81 - 87
DESCRIPTION- DORRIES ET AL., J. NEUROVIROL., (2003), vol. 9, no. 1, pages 81 - 87
DESCRIPTION- DORRIES ET AL., VIROLOGY, (1994), vol. 198, pages 59 - 70
DESCRIPTION- DUBOIS ET AL., AIDS, (1996), vol. 10, pages 353 - 358
DESCRIPTION- DUREZ ET AL., ARTHRITIS RHEUM., (2002), vol. 46, no. 9S, page 536
DESCRIPTION- DWORKIN ET AL., CURR. CLIN. TOP. INFECT. DIS., (2002), vol. 22, pages 181 - 195
DESCRIPTION- ELICES ET AL., CELL, (1990), vol. 60, pages 577 - 584
DESCRIPTION- ELPHICK ET AL., SCIENCE, (2004), vol. 306, pages 1380 - 1383
DESCRIPTION- ERNST ET AL., RADIOLOGY, (1999), vol. 210, pages 439 - 543
DESCRIPTION- FERGUSON ET AL., BRAIN, (1997), vol. 120, pages 393 - 399
DESCRIPTION- FERRANTE ET AL., MULTIPLE SCLEROSIS, (1998), vol. 4, pages 49 - 54
DESCRIPTION- GARRELS ET AL., AM. J. NEURORADIOL., (1996), vol. 17, pages 597 - 600
DESCRIPTION- GESCHWIND ET AL., J. NEUROVIROL., (2001), vol. 7, pages 353 - 357
DESCRIPTION- GIBSON ET AL., J. MED. VIROL., (1993), vol. 39, pages 278 - 281
DESCRIPTION- HEMLER ET AL., ANNU. REV. IMMUNOL., (1990), vol. 8, pages 365 - 400
DESCRIPTION- HENSON ET AL., NEUROLOGY, (1991), vol. 41, pages 1967 - 1971
DESCRIPTION- HOCHBERG, BIOMETRIKA, (1988), vol. 75, pages 800 - 802
DESCRIPTION- HOFFMANN ET AL., J. NEUROL. NEUROSURG. PSYCHIATRY, (2003), vol. 74, pages 1142 - 1144
DESCRIPTION- HOLMAN ET AL., NEUROEPIDEMIOL., (1998), vol. 17, pages 303 - 309
DESCRIPTION- HURLEY ET AL., J. NEUROPSYCHIATRY CLIN. NEUROSCI., (2003), vol. 15, pages 1 - 6
DESCRIPTION- IFNB MS STUDY GROUP, NEUROLOGY, (1993), vol. 43, pages 655 - 661
DESCRIPTION- IFNB MS STUDY GROUP, NEUROLOGY, (1996), vol. 47, pages 889 - 894
DESCRIPTION- ISAAC ET AL., NEUROLOGY, (1988), vol. 38, pages 1511 - 1515
DESCRIPTION- ISSEKUTZ ET AL., CURR. OPIN. IMMUNOL., (1992), vol. 4, pages 287 - 293
DESCRIPTION- JACOBS ET AL., ANN. NEUROL., (1996), vol. 39, pages 285 - 289
DESCRIPTION- JACOBS ET AL., AUN. NEUROL., (1996), vol. 39, pages 285 - 289
DESCRIPTION- JOHNSON ET AL., NEUROLOGY, (1995), vol. 45, pages 1268 - 1276
DESCRIPTION- KAPPOS ET AL., LANCET, (1999), vol. 353, pages 964 - 969
DESCRIPTION- KAPPOS ET AL., NEUROLOGY, (2005), vol. 65, pages 40 - 47
DESCRIPTION- KENT ET AL., J. NEUROIMMUNOL., (1995), vol. 58, pages 1 - 10
DESCRIPTION- KHOURY ET AL., NEUROLOGY, (1994), vol. 44, pages 2120 - 2124
DESCRIPTION- KITAMURA ET AL., J. INFECT. DIS., (1990), vol. 161, pages 1128 - 1133
DESCRIPTION- KLEINSCHMIDT; DEMASTERS; TYLER, N. ENGL. J. MED., (2005), vol. 353, pages 369 - 374
DESCRIPTION- KNOWLES ET AL., J. MED. VIROL., (1999), vol. 59, pages 474 - 479
DESCRIPTION- KNOWLES ET AL., J. MED. VIROL., (2003), vol. 71, pages 115 - 123
DESCRIPTION- KNOWLES; SASNAUSKAS, J. VIROL. METHODS., (2003), vol. 109, pages 47 - 54
DESCRIPTION- KORALNIK, CURR. OPT. NEUROL., (2004), vol. 17, pages 365 - 370
DESCRIPTION- KORNEK ET AL., AM. J. PATHOL., (2000), vol. 157, pages 267 - 276
DESCRIPTION- KOZOVSKA ET AL., NEUROLOGY, (1999), vol. 53, pages 1692 - 1697
DESCRIPTION- LANGER-GOULD ET AL., N. ENG. J. MED., (2005), vol. 353, pages 375 - 381
DESCRIPTION- LANGER-GOULD ET AL., N. ENGL. J. MED., (2005), vol. 353, pages 375 - 381
DESCRIPTION- LOBB; HEMLER, J. CLIN. INVEST., (1994), vol. 94, pages 1722 - 1728
DESCRIPTION- LONG ET AL., EXP. HEMATOL., (1992), vol. 20, pages 288 - 301
DESCRIPTION- MAMIDI ET AL., J. NEUROVIROL., (2002), vol. 8, pages 158 - 167
DESCRIPTION- MCDONALD ET AL., ANN. NEUROL., (2001), vol. 50, pages 121 - 127
DESCRIPTION- MCFARLAND ET AL., MULTIPLE SCLEROSIS, (2002), vol. 8, pages 40 - 51
DESCRIPTION- MOLYNEUX ET AL., ANN. NEUROL., (1998), vol. 43, pages 332 - 339
DESCRIPTION- OLSEN ET AL., RADIOLOGY, (1988), vol. 169, pages 445 - 448
DESCRIPTION- O'NEILL E, IMMUNOLOGY, (1991), vol. 72, pages 520 - 525
DESCRIPTION- O'RIORDAN ET AL., BRAIN, (1998), vol. 121, pages 495 - 503
DESCRIPTION- PADGETT ET AL., PROG. CLIN. BIOL. RES., (1983), vol. 105, pages 107 - 117
DESCRIPTION- PETERSON ET AL., J. NEUROPATHY EXP. NEUROL., (2002), vol. 61, pages 539 - 546
DESCRIPTION- POST ET AL., AM. J. NEURORADIOL., (1999), vol. 20, pages 1896 - 1906
DESCRIPTION- PRISMS STUDY GROUP, LANCET, (1998), vol. 352, pages 1498 - 1504
DESCRIPTION- PRISMS STUDY GROUP, NEUROLOGY, (2001), vol. 56, pages 1628 - 1636
DESCRIPTION- PRZEPIORKA ET AL., BONE MARROW TRANSPLANT, (1997), vol. 20, pages 983 - 987
DESCRIPTION- RAINE ET AL., LAB. INVEST., (1990), vol. 63, pages 476 - 489
DESCRIPTION- RANKIN ET AL., J. RHEUMATOL, (1995), vol. 22, pages 777 - 79
DESCRIPTION- REDINGTON ET AL., ARCH. NEUROL., (2002), vol. 59, pages 712 - 718
DESCRIPTION- REP ET AL., J. NEUROIMMUNOL., (1996), vol. 67, pages 111 - 118
DESCRIPTION- RUDICK ET AL., NEUROLOGY, (1998), vol. 50, pages 1266 - 1272
DESCRIPTION- RUNMARKER; ANDERSON, BRAIN, (1993), vol. 116, pages 117 - 134
DESCRIPTION- SAILER ET AL., NEUROLOGY, (1999), vol. 52, pages 599 - 606
DESCRIPTION- SALMAGGI, NEUROL. SCI., (2001), vol. 22, pages 17 - 20
DESCRIPTION- SETH ET AL., J. NEUROVIROL., (2003), vol. 9, pages 236 - 246
DESCRIPTION- SHITRIT ET AL., TRANSPL. INT., (2005), vol. 17, pages 658 - 665
DESCRIPTION- SIMON ET AL., NEUROLOGY, (2000), vol. 55, pages 185 - 192
DESCRIPTION- SPONZILLI ET AL., NEUROLOGY, (1975), vol. 25, pages 664 - 668
DESCRIPTION- SPRINGER ET AL., CELL, (1994), vol. 76, pages 301 - 314
DESCRIPTION- STEFFEN ET AL., AM. J. PATH., (1994), vol. 145, pages 189 - 201
DESCRIPTION- SUNDSFJORD ET AL., J. INFECT. DIS., (1994), vol. 169, pages 485 - 490
DESCRIPTION- TANTISIRIWAT ET AL., CLIN. INFECT. DIS., (1999), vol. 28, pages 1152 - 1154
DESCRIPTION- THOMPSON ET AL., ANN. NEUROL., (1991), vol. 9, pages 53 - 62
DESCRIPTION- THOMPSON ET AL., NEUROLOGY, (1992), vol. 42, pages 60 - 63
DESCRIPTION- TORNATORE ET AL., ANN. NEUROL., (1992), vol. 31, pages 454 - 462
DESCRIPTION- TRAPP ET AL., N. ENGL. J. MED., (1998), vol. 338, pages 278 - 285
DESCRIPTION- VAGO ET AL., J. ACQUIR. IMM. DEFIC. SYNDR. HUM. RETROVIROL., (1996), vol. 12, pages 139 - 146
DESCRIPTION- VAN ASSCHE ET AL., N. ENGL. J. MED., vol. 353, pages 362 - 368
DESCRIPTION- WASHINGTON ET AL., ANN. NEUROL., (1994), vol. 35, pages 89 - 97
DESCRIPTION- WEBER ET AL., AIDS, (1994), vol. 8, pages 49 - 57
DESCRIPTION- WEBER ET AL., J. INFECT. DIS., (1994), vol. 169, pages 1138 - 1141
DESCRIPTION- WHITAKER ET AL., MULTIPLE SCLEROSIS, (1995), vol. 1, pages 37 - 47
DESCRIPTION- WILLOUGHBY ET AL., ANN. NEUROL., (1989), vol. 25, pages 43 - 44
DESCRIPTION- YEDNOCK ET AL., NATURE, (1992), vol. 356, pages 63 - 66
DESCRIPTION- ZANG ET AL., J. NEUROIMMUNOL., (2001), vol. 112, pages 174 - 180
EXAMINATION- KNOWLES W A ET AL, "Comparison of cell culture-grown JC virus (primary human fetal glial cells and the JCI cell line) and recombinant JCV VP1 as antigen for the detection of anti-JCV antibody by haemagglutination inhibition.", JOURNAL OF VIROLOGICAL METHODS APR 2003, (200304), vol. 109, no. 1, ISSN 0166-0934, pages 47 - 54
EXAMINATION- KNOWLES W A ET AL, "Comparison of cell culture-grown JC virus (primary human fetal glial cells and the JCI cell line) and recombinant JCV VP1 as antigen for the detection of anti-JCV antibody by haemagglutination inhibition.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (200304), Database accession no. NLM12668267
EXAMINATION- RAFFEL JOEL B ET AL, "Assay selection affects John Cunningham virus serostatus classification in multiple sclerosis.", ANNALS OF NEUROLOGY AUG 2012, (201208), vol. 72, no. 2, ISSN 1531-8249, pages 295 - 296 , aut
EXAMINATION- RAFFEL JOEL B ET AL, "Assay selection affects John Cunningham virus serostatus classification in multiple sclerosis.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (201208), Database accession no. NLM22926862
EXAMINATION- GARY BLOOMGREN ET AL, "Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy", NEW ENGLAND JOURNAL OF MEDICINE, (20120517), vol. 366, no. 20, doi:10.1056/NEJMoa1107829, ISSN 0028-4793, pages 1870 - 1880, XP055049527
OPPOSITION- Ahsan Nasimul; Shah Keerti V, "Polyomaviruses and human diseases.- chapter 1", Retinal Degenerative Diseases: Advances in Experimental Medicine and Biology, Springer, US, US, (20060101), vol. 577, ISSN 0065-2598, pages 1 - 18, XP008177124
OPPOSITION- Anat Achiron, Et Al, "Does the Flap of a Butterfly's Wings in Brazil set off a Tornado in Texas? The JC Virus Story in Multiple Sclerosis", IMAJ, (20050101), pages 283 - 285, IMAJ, URL: https://www.ima.org.il/FilesUploadPublic/IMAJ/0/50/25210.pdf, (20201014), XP055739892
OPPOSITION- Annika Lundstig, Et Al, "Serological Diagnosis of Human Polymavirus Infection", Polymaviruses and Human Diseases, (20060101), pages 96 - 101, XP055740377
OPPOSITION- Anonymous, "Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate", US National Library of Medicine ClinicalTrials.gov, (20090602), pages 1 - 10, US National Library of Medicine ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/results/NCT00083759?view=results, (20201015), XP055740404
OPPOSITION- BERGER et al., "Progressive Multifocal Leukoencephalopathy and Natalizumab - Unforseen Consequences", New England Journal of Medicine, (20050000), vol. 353, pages 414 - 16, XP002568726
OPPOSITION- LANGER-GOULD ANNETTE ET AL, "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US, (20050728), vol. 353, no. 4, ISSN 1533-4406, pages 375 - 381, XP002568725
OPPOSITION- VAN ASSCHE et al., "Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease", New England Journal of Medicine, (20050000), vol. 353, pages 362 - 8, XP002568728
OPPOSITION- Wendy A Knowles, "Discovery and Epidemiology of the Human Polyomaviruses BK Virus (BKV) anf JC Virus (JCV)", Polymaviruses and Human Diseases, (20060101), pages 19 - 45, XP055740282
OPPOSITION- GORELIK et al., "Anti-JC Virus Antibodies: Implications for PML Risk Stratification", Ann Neurol, (20100000), vol. 68, doi:10.1002/ana.22128, pages 295 - 303, XP055136721
OPPOSITION- Joseph R. Berger, Sidney A. Houff, Julie Gurwell, Nubia Vega, Craig S. Miller, Robert J. Danaher, "JC virus antibody status underestimates infection rates : JCV Antibody Status", Annals of Neurology, John Wiley and Sons, BOSTON, US, BOSTON, US, (20130701), vol. 74, no. 1, doi:10.1002/ana.23893, ISSN 0364-5134, pages 84 - 90, XP055740405
OPPOSITION- Hou Jean; Seth Pankaj; Major Eugene O, "JC virus can infect human immune and nervous system progenitor cells: implications for pathogenesis.", Retinal Degenerative Diseases: Advances in Experimental Medicine and Biology, Springer, US, US, (20060101), vol. 577, doi:10.1007/0-387-32957-9_19, ISSN 0065-2598, pages 266 - 273, XP008164417
OPPOSITION- MILLER et al., "A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis", New England Journal of Medicine, (20030000), vol. 348, doi:10.1056/NEJMoa020696, pages 15 - 23, XP008076675
OPPOSITION- B.K. KLEINSCHMIDT-DEMASTERS, AND KENNETH L. TYLER, "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis", New England Journal of Medicine, Massachusetts Medical Society, US, US, (20050728), vol. 353, no. 4, doi:10.1056/NEJMoa051782, ISSN 0028-4793, pages 369 - 374, XP008131037
OPPOSITION- STOLT et al., "Seroepidemiology of the human polyomaviruses", Journal of General Virology, (20030000), vol. 84, doi:10.1099/vir.0.18842-0, pages 1499 - 1504, XP055201809
OPPOSITION- VISCIDI et al., "Serological Cross-Reactivities between Antibodies to Simian Virus 40, BK Virus, and JC virus assessed by Virus-Like-Particle-Based Enzyme Immunoassays", Clinical and Diagnostic Laboratory Immunology, (20030000), doi:10.1128/CDLI.10.2.278-285.2003, pages 278 - 285, XP055162298
SEARCH- Anonymous, "BIOGEN IDEC AND ELAN ANNOUNCE VOLUNTARY SUSPENSION OF TYSABRI", (20050228), URL: http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1324695, (20120726), XP055033918 [Y] 1-18 * the whole document *
SEARCH- LANGER-GOULD ANNETTE ET AL, "Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, (20050728), vol. 353, no. 4, ISSN 0028-4793, pages 375 - 381, XP009123696 [Y] 1-18 * the whole document *
SEARCH- STEINMAN LAWRENCE, "Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, (20050601), vol. 4, no. 6, ISSN 1474-1776, pages 510 - 518, XP009123807 [A] 1-18 * the whole document *
SEARCH- VAN ASSCHE GERT ET AL, "Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, (20050728), vol. 353, no. 4, ISSN 1533-4406, pages 362 - 368, XP009123817 [Y] 1-18 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents